Valneva SE announced that the EMA will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a systematic review of Valneva’s single-dose chikungunya… read more.
People who have had COVID-19 are at increased risk of developing certain inflammatory diseases of the airways, such as asthma, hay fever and chronic sinusitis. However, vaccination against… read more.
Researchers at Arizona State University have developed a breakthrough diagnostic tool that could transform how quickly and reliably we detect illnesses like COVID-19, Ebola, AIDS or Lyme disease…. read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Xofluza. The marketing authorisation… read more.
Merck Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended the approval of Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization… read more.
Ivermectin administered to the whole population significantly reduces malaria transmission, offering new hope in the fight against the disease. The BOHEMIA trial, the largest study on ivermectin for… read more.
Researchers at the University of Pittsburgh have identified a new way of predicting whether a kidney donor and recipient are a good match for transplantation. The findings, published… read more.
A new study by Chinese scientists has sparked hope for improved management of sepsis, a potentially life-threatening medical emergency. The research suggests that statins, a commonly-used cholesterol-busting medication,… read more.
A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few antibiotics… read more.
Atara Biotherapeutics , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,… read more.
NICE (UK): Leniolisib is recommended, within its marketing authorisation, for treating activated phosphoinositide 3‑kinase delta syndrome (APDS) in people 12 years and over. Leniolisib is recommended only if… read more.
KalVistA Pharmaceuticals Inc. announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
